Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA‐B*5701 Screening as a Risk‐Mitigation Measure

INTRODUCTION: Human leukocyte antigen (HLA)‐B*5701 screening identifies patients at increased risk for abacavir (ABC) hypersensitivity reaction (HSR). Screening was adopted in GlaxoSmithKline and ViiV Healthcare clinical trials in 2007 and human immunodeficiency virus treatment guidelines in 2008. C...

Descripción completa

Detalles Bibliográficos
Autores principales: Stainsby, Chris M., Perger, Teodora M., Vannappagari, Vani, Mounzer, Karam C., Hsu, Ricky K., Henegar, Cassidy E., Oyee, James, Urbaityte, Rimgaile, Lane, Charlotte E., Carter, Lindsay M., Pakes, Gary E., Shaefer, Mark S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590466/
https://www.ncbi.nlm.nih.gov/pubmed/30414209
http://dx.doi.org/10.1002/phar.2196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590466/
https://www.ncbi.nlm.nih.gov/pubmed/30414209
http://dx.doi.org/10.1002/phar.2196

Ejemplares similares